ClinicalTrials.gg
Not yet recruitingNCT07303322MINORA-WOMENUpdated Nov 4, 2026

Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)

A Phase 3 interventional study of N1087 and Placebo in Female Pattern Hair Loss and Female Pattern Hair Loss, Androgenic Alopecia, sponsored by Eurofarma Laboratorios S.A.. Not yet recruiting at 1 site in Brazil. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Eurofarma Laboratorios S.A. · Phase 3, Interventional, and Treatment

Updated Nov 4, 2026First site in BrazilStudy contact changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
372
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies in Alopecia with a site in Brazil — 8 open to participants now, 8 under way, 5 of them phase 3. Alopecia · Brazil.

Planned enrollment
2nd of 14
372 · median 133
Started
2027
with 1 other
Phase 3
7 of 14
5 open now
Registered
9th of 14
by date
Lead sponsor
3 of 14
Eurofarma Laboratorios S.A.

Among the 14 studies in Alopecia with a site in Brazil, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2027, is one of 7 in phase 3, and was the 9th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 128 are open to participants now.

Browse Alopecia studies →

Open to participants now

8 of the 14 studies in Alopecia with a site in Brazil are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 76 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 48 (63%) stop at 75 or younger; 10 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Alopecia with a site in Brazil, or all of them as a file.
02

Study summary

This is a Phase 3, prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial designed to evaluate the efficacy and safety of N1087 in women with female pattern hair loss (FPHL). Participants will receive either N1087 or placebo for 24 weeks. The study includes a titration period starting at 0.5 mg and increasing up to 2 mg daily, followed by treatment at the maximum tolerated dose. The primary objective is to assess changes in non-vellus hair density in the target scalp area after 24 weeks. Secondary objectives include changes in terminal hair density, hair thickness, global photographic assessment, quality of life, and participant satisfaction. Safety will be monitored through adverse events, vital signs, and laboratory tests. Approximately 372 participants will be randomized in a 2:1 ratio (N1087 vs. placebo) across about 10 research centers in Brazil.

Read the detailed description

This Phase 3 clinical trial is a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of N1087 in women with female pattern hair loss (FPHL), also known as female androgenetic alopecia. FPHL is a chronic, progressive condition characterized by gradual thinning of hair and reduced density, primarily in the frontal and vertex regions of the scalp. Current treatment options are limited, and topical minoxidil, although widely used, is not approved for women in Brazil and presents adherence challenges. Low-dose oral minoxidil has shown promising efficacy and safety in clinical practice and literature, but high-quality controlled trials are lacking.

Participants will be randomized in a 2:1 ratio to receive N1087 or placebo for 24 weeks. The intervention begins with an 8-week titration period (0.5 mg/day for 2 weeks, then 1 mg, 1.5 mg, and 2 mg every 2 weeks) followed by 16 weeks at the maximum tolerated dose (up to 2 mg/day). The primary endpoint is the change from baseline in non-vellus hair density (≥0.03 mm diameter) in the target area at Week 24, assessed by standardized digital phototrichogram. Secondary endpoints include changes in terminal hair density, total hair density, hair shaft thickness, reversal of follicular miniaturization, global photographic assessment (Investigator Global Assessment), quality of life (WAA-QoL questionnaire), and participant satisfaction. Safety assessments include adverse events, vital signs, ECG, and laboratory tests.

The study will enroll approximately 372 participants across 10 sites in Brazil, with eligibility criteria including women aged 18-60 years, Sinclair scale 2-4, and no recent treatments for FPHL. Exclusion criteria include other causes of alopecia, uncontrolled hypertension, cardiovascular conditions, hormonal disorders, and pregnancy. The total study duration per participant is approximately 36 weeks (up to 12 weeks screening/washout, 8 weeks titration, 16 weeks treatment). A Data Monitoring Committee will oversee safety.

03

Conditions studied

  • Female Pattern Hair Loss
  • Female Pattern Hair Loss, Androgenic Alopecia

Browse trials for

Keywords

  • Androgenetic Alopecia
  • Hair Loss
  • Female Pattern Hair Loss
  • Alopecia
  • Randomized Controlled Trial
  • Phase 3
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants aged ≥18 years and ≤60 years at the time of signing the form.
  • Presentation of female pattern hair loss in stages 2 to 4 of the Sinclair scale (Women's Alopecia Severity Scale - WASS), based on the Investigator's clinical examination.
  • Absence of specific treatment for female pattern hair loss (FPHL) in the last 6 months or history of specific treatment for FPHL lasting ≤30 days in the last 6 months. Participants currently using specific treatment for FPHL or with prior use lasting >30 days in the last 6 months must complete a 3-month before the Randomization Visit (RV).
  • Willing to agree to all procedures and assessments required by the clinical trial, including a permanent tattoo applied to the scalp and shaving of the target area.
  • Willing to maintain hair style, length, and color throughout the study.
  • Willing to maintain consistent use of hair care products and general hair care routine during the entire study.

Exclusion criteria

Exclusion Criteria:

  • Participant presenting other causes of alopecia, such as: alopecia areata, scarring alopecia, traction alopecia, nutritional deficiency, monilethrix, trichotillomania, trichothiodystrophy, chemotherapy-induced alopecia.
  • Participant who experienced telogen effluvium in the last 6 months, such as after childbirth, infection, intense stress.
  • Participant presenting other dermatological conditions on the scalp, such as: seborrheic dermatitis, psoriasis, eczema, scalp mycosis.
  • Participant presenting signs or symptoms of hyperandrogenism, such as: hirsutism, moderate to severe acne.
  • Participant with previous diagnosis of hormonal disorders, such as: polycystic ovary syndrome, ovarian or adrenal tumors.
  • Participant with previous diagnosis of pituitary disorders, such as: prolactinoma, panhypopituitarism.
  • Participant presenting uncontrolled thyroid disease.
  • Participant with previous diagnosis of diseases or collagen disorders, such as: systemic lupus erythematosus, dermatomyositis, scleroderma.
  • Participant in use of hormonal therapy initiated or changed in the last 6 months.
  • Participant who has received an organ transplant.
  • Participant who underwent physical treatments for hair loss in the last 6 months, such as: microneedling, laser, -rich plasma. Note: in this case, the participant must complete a 3-month .
  • Participant with history of hair transplant.
  • Participant who uses hair extensions.
  • Participant presenting severe uncontrolled hypertension (systolic blood pressure [SBP] >180 mmHg or diastolic blood pressure [DBP] >110 mmHg).
  • Participant presenting confirmed orthostatic hypotension (sustained reduction of SBP ≥20 mmHg or DBP ≥10 mmHg within 3 minutes after standing).
  • Participant presenting arterial hypotension (SBP \<90 mmHg or DBP \<60 mmHg).
  • Participant with previous diagnosis or suspected pulmonary hypertension associated with mitral stenosis.
  • Participant with previous diagnosis of acute myocardial infarction.
  • Participant with previous diagnosis or suspected pheochromocytoma.
  • Participant presenting history of peripheral edema, lymphedema, or ascites.
  • Participant with history or risk factor for pericardial effusion.
  • Participant with previous diagnosis of other moderate to severe cardiovascular, renal, or hepatic diseases.
  • History of any in the last 5 years, except successfully treated non- basal cell or squamous cell carcinoma of the skin.
  • Participant in current use of potent vasodilators, such as: hydralazine and isosorbide.
  • Participant with known allergy or to minoxidil or any component of the formulation.
  • Participant presenting hair styles that, in the Investigator's opinion, prevent study assessments, such as: permanent braids, dreadlocks, box braids, nagô.
  • Participant who is pregnant, breastfeeding, or has potential to become pregnant and does not agree to use a method during the clinical trial.
  • Participant presenting any condition that, in the Investigator's opinion, makes the participant unsuitable for participation in the trial.
  • Participant who has participated in clinical trial protocols in the last 12 months, unless the Investigator considers there may be direct benefit.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
372 participants (estimated)

Study arms

  • Experimental
    N1087

    Participants will receive N1087, starting at 0.5 mg/day and titrated every 2 weeks (1 mg, 1.5 mg, up to 2 mg/day) during an 8-week titration period, followed by 16 weeks at the maximum tolerated dose (up to 2 mg/day). Administered orally once daily for a total of 24 weeks.

    Drug: N1087

  • Placebo comparator
    Placebo

    Participants will receive placebo, administered once daily for 24 weeks, following the same titration schedule as the experimental arm to maintain blinding.

    Drug: Placebo

Interventions

  • DrugN1087

    N1087 is an oral solution administered in drops. Treatment begins with an 8-week titration period: 0.5 mg/day for 2 weeks, then 1 mg/day, 1.5 mg/day, and up to 2 mg/day every 2 weeks. After titration, participants continue for 16 weeks at the maximum tolerated dose (up to 2 mg/day). Administered orally once daily for a total of 24 weeks.

  • DrugPlacebo

    Placebo administered once daily for 24 weeks, following the same titration schedule as the experimental arm to maintain blinding.

06

What researchers measure

Primary outcomes

  1. Change from baseline in non-vellus hair density (≥0.03 mm diameter) in the target scalp area at Week 24

    Non-vellus hair density (≥0.03 mm diameter) will be measured in the target scalp area using standardized digital phototrichogram. The primary endpoint is the absolute change from baseline to Week 24.

    Time frame: 24 weeks

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jul 2028, 18 months later.

Of 28 phase 3 interventional studies under Alopecia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 18 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 24, 2025
StartEst.
Jan 2027
Primary completionEst.
Jul 2028
CompletionEst.
Aug 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in Brazil
Show site
  • Eurofarma Laboratórios S.A · Itapevi, Brazil
Nov 4, 2026
Contact
Study contact changed: l•••@eurofarma.com · •••8421→n•••@eurofarma.com · •••9500; added t•••@eurofarma.com. See the current contact
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    1 site added — first site in Brazil
    Show site
    • Eurofarma Laboratórios S.A · Itapevi, Brazil
    Contact Study contact changed: l•••@eurofarma.com · •••8421→n•••@eurofarma.com · •••9500; added t•••@eurofarma.com. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07303322
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Jan 2027 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Natalia Silva Di Gianni
Contact
natalia.gianni@eurofarma.com
+55 11 4144-9500
Taís Mendonça dos Santos
Contact
tais.santos@eurofarma.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion